Medical experts say the psychological complaints may not be surprising. Semaglutide, the active ingredient in Ozempic and Wegovy, affects not only the gut but also brain pathways tied to reward and motivation. The drug alters activity in cells that regulate dopamine and serotonin — chemicals linked to pleasure, appetite and mood — helping reduce cravings for high-fat and sugary foods by making them less rewarding.
Some users describe the experience as “anhedonia,” or an inability to feel pleasure, sometimes dubbed online as the “Ozempic personality.” Patients report losing interest in hobbies, social activities and even food itself, describing a persistent sense of emotional flatness or indifference. While many people tolerate the drugs without psychological symptoms and there is no conclusive evidence the effects are permanent, physicians caution that rapid weight loss, shifting body image and changes in brain chemistry together may affect mental health — raising new questions about long-term risks as prescriptions continue to surge.
Across Reddit threads and patient forums, some GLP-1 users describe an unsettling shift that goes beyond appetite control. Posters say they feel emotionally muted — not depressed, but detached — reporting that work feels less meaningful, creativity has dulled, and activities that once delivered pleasure or motivation no longer register. Several users describe losing the “dopamine hits” that once powered daily routines, leaving them feeling calm yet indifferent, as if rewards on the other side of effort have disappeared. While these accounts remain anecdotal, the consistency of the reports is drawing attention as researchers examine whether drugs designed to quiet food cravings may also blunt broader reward responses in the brain.
A recent New Yorker article, “Can Ozempic Cure Addiction?”, described similar effects. One participant said alcohol no longer appealed to her at all: “My brain recognized [wine] — like, oh, that’s what you used to want — but my body had no desire for it.” This is like desire overridden by biology rather than choice. For some GLP-1 users, the loss of craving feels similarly automatic, raising deeper questions about how much of human motivation is chemically mediated.
According to the nonpartisan health policy organization KFF, roughly 12% of U.S. adults — more than 31 million people — used a GLP-1 drug in 2024, primarily for diabetes and obesity treatment. Several medications are now also approved to treat kidney disease, sleep apnea, and cardiovascular risk, expanding their reach even further.
READ MORE OZEMPIC AND MOUNJARO LEGAL NEWS
“They’re being studied for every purpose you can conceive of,” said Timothy Anderson, a health services researcher at the University of Pittsburgh and author of a November 2025 JAMA Internal Medicine editorial about anti-obesity medications. KFF reported that nearly four in ten adults and a quarter of children enrolled in Medicaid have obesity, meaning expanded coverage could provide access for millions. Coverage remains uneven, however: as of January 2026, only 13 state Medicaid programs covered GLP-1s for obesity treatment under fee-for-service plans. Meanwhile, prescriptions — and spending — have risen sharply since 2019, driven largely by semaglutide drugs such as Ozempic and Wegovy and tirzepatide medications including Mounjaro and Zepbound.
Add treatment for addiction – from alcohol to nicotine to gambling — and prescriptions will likely climb into the tens of millions. The debate may shift from effectiveness to disclosure — and whether patients were adequately warned about risks that extend beyond weight loss. As patient reports grow and researchers investigate the phenomenon, attorneys are watching closely to see whether disclosure obligations kept pace with the drugs’ explosive adoption.
Source link
